Biphenyl CompoundsTetrazolesAngiotensin II Type 1 Receptor BlockersAntihypertensive AgentsAngiotensin Receptor AntagonistsReceptor, Angiotensin, Type 1AmlodipineHydrochlorothiazideDiabetic NephropathiesAngiotensin IIReceptor, Angiotensin, Type 2HypertensionFumaratesDouble-Blind MethodRenin-Angiotensin SystemReceptors, AngiotensinLosartanAlbuminuriaAngiotensin-Converting Enzyme InhibitorsBlood PressureReceptors, Thromboxane A2, Prostaglandin H2Economics, PharmaceuticalCost SavingsDrug Therapy, CombinationImidazolidinesDiabetes Mellitus, Type 2BenzimidazolesBenzoatesDose-Response Relationship, DrugLife ExpectancyAmidesTreatment OutcomeSteroid 16-alpha-HydroxylaseMarkov ChainsAtenololProteinuriaCreatinineReninAngiotensin IFibrosisKidneyHeart FailureImidazolesDrug CombinationsAmiodaroneValineBiotransformationKv1.5 Potassium ChannelDiureticsPPAR gammaRats, Inbred SHRHypertriglyceridemiaVasoconstrictor AgentsThioctic AcidCell TransdifferentiationCross-Over StudiesSwitzerlandSecondary Prevention15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic AcidNephritis, InterstitialMulticenter Studies as TopicThromboxane A2Atrial FibrillationKidney Failure, ChronicSingle-Blind MethodHypertrophy, Left VentricularCaptoprilChromatography, High Pressure LiquidHeartTime FactorsDiabetes ComplicationsAdministration, OralProspective StudiesRandom AllocationReceptors, ProstaglandinPPAR alphaCalcium Channel BlockersRats, Sprague-DawleyStroke VolumeInjections, IntraventricularCost-Benefit AnalysisRats, Inbred WKYSystoleHeart RateRadioligand AssaySteroid HydroxylasesVentricular RemodelingFollow-Up StudiesTreatment FailureTransforming Growth Factor beta1Mesenteric ArteriesAortaMyocardiumArea Under CurveGlomerular Filtration RateMetabolic Syndrome XBiological MarkersRats, WistarDisease Models, AnimalAryl Hydrocarbon Hydroxylases